Boswellia oil, its fractions and compositions for enhancing brain function
The present disclosure relates to non-acidic extracts or fractions selected from a Boswellia low polar gum resin extract fraction (BLPRE), a Boswellia volatile oil fraction (BVOIL), and a Boswellia oil fraction (BOIL) and their compositions. BLPRE, BOIL, and BVOIL are each derived from the gum resin of a Boswellia species. These compositions are useful for improving mental condition, enhancing brain functions such as cognition, memory, learning, communication and brain health, for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases. Additionally, BOIL, BVOIL, and mixtures of BOIL and BVOIL are useful for enhancing the bioavailability of a biological agent.
1. A therapeutic method, comprising administering a composition to an individual in need thereof;
said composition comprising an oil extract derived from a Boswellia species, said oil extract being free of acidic compounds;
said composition further comprising an optional bioactive agent;
said oil extract being present in an amount effective to enhance at least one of:
a) cognitive function in said individual; and
b) bioavailability of said bioactive agent, said oil extract being prepared by a process comprising:
extraction of a Boswellia gum resin with a water-immiscible non-polar solvent to produce a non-polar solvent extract; and
washing the non-polar solvent extract with aqueous alkali to remove boswellic acids from the non-polar solvent extract to produce an intact Boswellia oil (BOIL); and
subjecting said BOIL to distillation to produce a non-volatile Boswellia oil component and a Boswellia volatile oil (BVOIL) recovered as a distillate from said distillation;
wherein said oil extract is selected from the group consisting of the non-volatile Boswellia oil component, BVOIL, BOIL, and a mixture thereof.
2. The therapeutic method of claim 1 , wherein said oil extract is present in an amount effective to enhance cognitive function in said individual;
wherein said individual suffers from a cognitive disorder selected from the group consisting of impaired memory, senile dementia, multi-infarct dementia, dyslexia, aphasia, myasthenia gravis, vascular dementia, mild cognitive impairment (MCI), Attention-deficient Hyperactivity Disorder (ADHD), Lewy body dementia, Wernicke-Korsakoff-syndrome, Alzheimer's, Parkinson's disease, hypoxia, anoxia, cerebrovascular insufficiency, epilepsy, myoclonus and hypocholinergic dysfunctions, and neurodegenerative disorders.
3. The therapeutic method of claim 2 , wherein said cognitive disorder is impaired memory.
4. The therapeutic method of claim 1 , wherein said composition comprises said oil extract and at least one component selected from the group consisting of a bioactive agent, a phytochemical, a vitamin, an amino acid, a mineral, a pharmaceutically acceptable excipient, a pharmaceutically acceptable vehicle, a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, and a mixture thereof.
5. The therapeutic method of claim 1 , wherein said Boswellia species is selected from the group consisting of Boswellia serrata, Boswellia carterii, Boswellia papyrifera, Boswellia ameero, Boswellia bullata, Boswellia dalzielii, Boswellia dioscorides, Boswellia elongata, Boswellia frereana, Boswellia nana, Boswellia neglecta, Boswellia ogadensis, Boswellia pirottae, Boswellia popoviana, Boswellia rivae, Boswellia sacra, Boswellia socotrana , and mixtures thereof.
6. The therapeutic method of claim 1 , wherein said composition comprises said bioactive agent,
said bioactive agent being selected from the group consisting of dietary supplements, herbal ingredients, nutraceuticals, functional ingredients, functional foods, nootropic agents, and mixtures thereof.
7. The therapeutic method according to claim 6 , wherein said bioactive agent is selected from the group consisting of natural antioxidants, neuroprotecting agents, anti-inflammatory agents, immune modulators, and mixtures thereof.
8. The therapeutic method according to claim 6 , wherein said composition comprises said bioactive agent, said bioactive agent being selected from the group consisting of:
at least one Boswellia serrata extract containing at least one boswellic acid,
a boswellic acid compound, and
a mixture thereof.
9. The therapeutic method according to claim 1 , wherein said composition comprises said bioactive agent, said bioactive agent being selected from the group consisting of:
at least one Boswellia serrata extract containing between about 20% and about 100% by weight of total boswellic acids.
10. The therapeutic method according to claim 1 , wherein said composition comprises said bioactive agent, said bioactive agent being selected from the group consisting of:
at least one Curcuma longa extract containing at least one curcuminoid,
a curcuminoid compound, and
a mixture thereof.
11. The therapeutic method according to claim 1 , wherein said composition comprises said bioactive agent, said bioactive agent being selected from the group consisting of said nootropic agents;
said nootropic agents being selected from the group consisting of:
at least one extract selected from the group consisting of Bacopa monnieri, Withania somnifera, Emblica officinalis , and Centella asiatica;
at least one phytochemical selected from the group consisting of Bacoside A3, Bacopaside II, Jujubogenin isomer of bacopasaponin C, Bacopasaponin C, Bacopaside I, Bacosine, Apigenin, Luteolin and Sitosterol-D-glucoside, curcumin, demethoxycurcumin, bisdemethoxycurcumin, monodemethylcurcumin, bisdemethylcurcumin, tetrahydrocurcumin, tetrahydrodemethoxycurcumin, tetrahydrobisdemethoxycurcumin and ar-turmerone, carnosic acid, rosmarinic acid, camphor, caffeic acid, ursolic acid, betulinic acid, rosmaridiphenol, rosmanol, salts thereof, and mixtures thereof.
12. The therapeutic method according to claim 1 , wherein said composition comprises at least one excipient selected from the group consisting of surfactants, binders, disintegrators, lubricants, preservatives, stabilizers, buffers and suspensions.
13. The therapeutic method according to claim 1 , wherein said composition is an oral dosage form.
14. The therapeutic method according to claim 1 , wherein said composition is a controlled release dosage form.
15. The therapeutic method according to claim 1 , wherein said composition contains:
an effective amount of said bioactive agent; and
said oil extract derived from said Boswellia species in an amount which is effective for enhancing the bioavailability of said bioactive agent.
16. The therapeutic method according to claim 15 , wherein said Boswellia species is selected from the group consisting of Boswellia serrata, Boswellia carterii, Boswellia papyrefera , and mixtures thereof.
17. The therapeutic method according to claim 15 , wherein said composition contains said oil extract in an amount which is effective for enhancing the bioavailability of said bioactive agent in a warm blooded animal in need thereof.
18. The therapeutic method according to claim 17 , wherein said bioactive agent is at least one agent selected from the group consisting of a functional ingredient, an herbal ingredient, a dietary supplement, a nutrient, an antioxidant, a vitamin, a mineral, an amino acid, an oil, and mixtures thereof.
19. The therapeutic method according to claim 17 , wherein the bioactive ingredient comprises one or more ingredients selected from herbal ingredients, dietary supplements, antioxidants, vitamins, minerals, amino acids, fatty acids, essential oils, fish oils, enzymes, glucosamine, chondroitin and probiotics or their salts or mixtures.
20. The therapeutic method according to claim 17 , wherein the bioactive ingredient comprises one or more ingredients selected from the group consisting of extracts or phytochemicals, said extracts or phytochemicals being derived from Withania somnifera, Bacopa monniera, Boswellia species, Curcuma species, Centella asiatica, Sphaeranthus indicus, Garcinia mangostana, Annona squamosa, Holoptelia integrifolia, Piper betel, Dolichos biflorus, Moringa oleifera, Murraya koenigii and mixtures thereof.
21. The therapeutic method according to claim 18 , wherein the herbal ingredient is derived from a Boswellia species, and includes one or more boswellic acids selected from the group consisting of α-boswellic acid, β-boswellic acid, 3-O-acetyl-α-boswellic acid, 3-O-acetyl-β-boswellic acid, 3-O-acetyl-11-keto-β-boswellic acid, and 3-O-acetyl-11-keto-β-boswellic acid.
22. The therapeutic method according to claim 20 , wherein the herbal ingredient is derived from a Boswellia species, and includes an extract comprising 3-acetyl-11-keto-β-boswellic acid.
23. The therapeutic method according to claim 20 , wherein the herbal ingredient is derived from a Curcuma species, and includes a component selected from the group consisting of curcumin, demethoxycurcumin, bisdemethoxycurcumin, monodemethylcurcumin, bisdemethylcurcumin, tetrahydrocurcumin, tetrahydrodemethoxy-curcumin, tetrahydrobisdemethoxycurcumin, ar-turmerone and mixtures thereof.
24. The therapeutic method according to claim 20 , wherein the herbal ingredient is derived from a Curcuma species, and includes curcumin.
25. The therapeutic method according to claim 18 , wherein the antioxidant comprises one or more ingredients selected from the group consisting of vitamin A, vitamin C, vitamin E, alpha-carotene, trans-beta-carotene, betacryptoxanthin, lycopene, lutein, zeaxanthin, pine bark bioflavonals complex, germanium, selenium and zinc.
26. The therapeutic method according to claim 18 , wherein the vitamin comprises:
a water-soluble vitamin selected from the group consisting of vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, folic acid, vitamin C, and mixtures thereof;
a fat-soluble vitamin selected from the group consisting of vitamin A, vitamin D, vitamin E and vitamin K, and mixtures thereof; or
a mixture of said water-soluble vitamin and said fat-soluble vitamin.
27. The therapeutic method according to claim 18 , wherein the mineral comprises one or more minerals selected from the group consisting of calcium, iron, zinc, vanadium, selenium, chromium, iodine, potassium, manganese, copper, and magnesium.
28. The therapeutic method according to claim 18 , wherein the amino acid comprises one or more amino acids selected from the group consisting of lysine, isoleucine, leucine, threonine, valine, tryptophan, phenylalanine, methionine, and 1-selenomethionine.
29. The therapeutic method according to claim 18 , wherein the oil comprises one or more oils selected from the group consisting of omega-3 fatty acids, flaxseed oil, fish oils, essential oils and volatile oils.
30. The therapeutic method according to claim 15 , wherein said Boswellia species is selected from the group consisting of Boswellia ameero, Boswellia bullata, Boswellia dalzielii, Boswellia dioscorides, Boswellia elongata, Boswellia frereana, Boswellia nana, Boswellia neglecta, Boswellia ogadensis, Boswellia pirottae, Boswellia popoviana, Boswellia rivae, Boswellia sacra and Boswellia socotrana.
31. A therapeutic method, comprising administering a composition to an individual in need thereof, said composition comprising an effective amount of a bioactive agent and an oil extract derived from a Boswellia species;
wherein said composition contains said oil extract in an amount which is effective for enhancing the bioavailability of said bioactive agent;
said oil extract being prepared by a process comprising:
extraction of a Boswellia gum resin with a water-immiscible non-polar solvent to produce a non-polar solvent extract;
washing the non-polar solvent extract with aqueous alkali to remove boswellic acids from the non-polar solvent extract to produce an intact Boswellia oil (BOIL); and
subjecting said BOIL to distillation to produce a non-volatile Boswellia oil component and a Boswellia volatile oil (BVOIL) recovered as a distillate from said distillation;
wherein said oil extract is selected from the group consisting of the non-volatile Boswellia oil component, BVOIL, BOIL, and a mixture thereof.
32. The therapeutic method according to claim 31 , wherein said bioactive agent is derived from a Boswellia species, and includes one or more boswellic acids selected from the group consisting of α-boswellic acid, β-boswellic acid, 3-O-acetyl-α-boswellic acid, 3-O-acetyl-β-boswellic acid, 3-O-acetyl-11-keto-α-boswellic acid and 3-O-acetyl-11-keto-β-boswellic acid.
33. The therapeutic method according to claim 31 , wherein said bioactive agent is derived from a Curcuma species, and includes a component selected from the group consisting of curcumin, demethoxycurcumin, bisdemethoxycurcumin, monodemethyl-curcumin, bisdemethylcurcumin, tetrahydro curcumin, tetrahydrodemethoxycurcumin, tetrahydrobisdemethoxycurcumin, ar-turmerone and mixtures thereof.